Literature DB >> 12888916

Sialic acids linked to glycoconjugates of Fas regulate the caspase-9-dependent and mitochondria-mediated pathway of Fas-induced apoptosis in Jurkat T cell lymphoma.

Osamu Suzuki1, Yoshihiro Nozawa, Masafumi Abe.   

Abstract

To clarify the functions of sialic acids linked to glycoconjugates of Fas in Fas-induced apoptosis, Jurkat T cells, untreated and treated with neuraminidase, were incubated with anti-Fas monoclonal antibody, CH11. Apoptosis of Jurkat T cells induced by incubation with CH11 was enhanced by the pre-treatment with neuraminidase. By flow cytometry sialylated glycoconjugates were detected on the cell surface of Jurkat T cells using LFA lectin, which specifically reacts with sialic acid, and pre-treatment with Vibrio Cholerae neuraminidase resulted in desialylation of Jurkat cell surface glycoconjugates. The enhancement of Fas-induced apoptosis by pre-treatment with neuraminidase was inhibited by z-VAD-fmk, a broad caspase inhibitor, and Ac-LEHD-CHO, an inhibitor of caspase-9, but not by Ac-IETD-CHO an inhibitor of caspase-8 or 6, imipramine, an inhibitor of acidic sphingomyelinase, glutathione, an inhibitor of neutral sphingomyelinase and Fumonisin B1, an inhibitor of ceramide synthase. Mitochondrial membrane potentials (Deltapsim) measured with a Mitocapture assay kit demonstrated that the loss of Deltapsim involved in Fas-induced apoptosis was enhanced by pre-treatment with neuraminidase. Furthermore, Western blot analysis using polyclonal antibody (C-20) against Fas detected Fas at about 45 kDa, and pre-treatment with neuraminidase resulted in a reduction of the molecular weight of Fas of about 8 kDa. These data suggest that the enhancement of Fas-induced apoptosis by pre-treatment with neuraminidase was mediated by a caspase-9 dependent pathway closely associated with the loss of Deltapsim, not by activation of caspase-8, -6 or acidic and neutral sphingomyelinases, and that sialic acid linked to glycoconjugates of Fas may regulate Fas-induced apoptosis in human T cell lymphoma.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12888916

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  7 in total

1.  Caspase-dependent drug-induced apoptosis is regulated by cell surface sialylation in human B-cell lymphoma.

Authors:  Osamu Suzuki; Masafumi Abe; Yuko Hashimoto
Journal:  Oncol Lett       Date:  2015-06-04       Impact factor: 2.967

2.  Mycoplasma alligatoris infection promotes CD95 (FasR) expression and apoptosis of primary cardiac fibroblasts.

Authors:  M E Hunt; D R Brown
Journal:  Clin Diagn Lab Immunol       Date:  2005-12

3.  Therapeutic Effect of Neuraminidase-1-Selective Inhibition in Mouse Models of Bleomycin-Induced Pulmonary Inflammation and Fibrosis.

Authors:  Irina G Luzina; Erik P Lillehoj; Virginia Lockatell; Sang W Hyun; Katerina N Lugkey; Akihiro Imamura; Hideharu Ishida; Christopher W Cairo; Sergei P Atamas; Simeon E Goldblum
Journal:  J Pharmacol Exp Ther       Date:  2020-11-02       Impact factor: 4.030

Review 4.  Regulation of the metastatic cell phenotype by sialylated glycans.

Authors:  Matthew J Schultz; Amanda F Swindall; Susan L Bellis
Journal:  Cancer Metastasis Rev       Date:  2012-12       Impact factor: 9.264

5.  Elevated expression of NEU1 sialidase in idiopathic pulmonary fibrosis provokes pulmonary collagen deposition, lymphocytosis, and fibrosis.

Authors:  Irina G Luzina; Virginia Lockatell; Sang W Hyun; Pavel Kopach; Phillip H Kang; Zahid Noor; Anguo Liu; Erik P Lillehoj; Chunsik Lee; Alba Miranda-Ribera; Nevins W Todd; Simeon E Goldblum; Sergei P Atamas
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2016-03-18       Impact factor: 5.464

Review 6.  Glycosylation in lymphoma: Biology and glycotherapy.

Authors:  Osamu Suzuki
Journal:  Pathol Int       Date:  2019-07-17       Impact factor: 2.534

Review 7.  ST6Gal1: Oncogenic signaling pathways and targets.

Authors:  Sajina Gc; Susan L Bellis; Anita B Hjelmeland
Journal:  Front Mol Biosci       Date:  2022-08-29
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.